Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Heron Therapeutics, Inc. (HRTX)

2.76   0.08 (2.99%) 12-02 16:00
Open: 2.64 Pre. Close: 2.68
High: 2.765 Low: 2.54
Volume: 2,213,589 Market Cap: 328(M)

Technical analysis

as of: 2022-12-02 4:23:30 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.07     One year: 4.76
Support: Support1: 2.53    Support2: 2.11
Resistance: Resistance1: 3.49    Resistance2: 4.07
Pivot: 2.92
Moving Average: MA(5): 2.68     MA(20): 3
MA(100): 3.8     MA(250): 5.03
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 17.2     %D(3): 12
RSI: RSI(14): 36.9
52-week: High: 10.46  Low: 2.19
Average Vol(K): 3-Month: 2,791 (K)  10-Days: 1,861 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HRTX ] has closed above bottom band by 32.5%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.77 - 2.79 2.79 - 2.8
Low: 2.51 - 2.53 2.53 - 2.54
Close: 2.73 - 2.77 2.77 - 2.79

Company Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Headline News

Thu, 17 Nov 2022
Heron Therapeutics (NASDAQ:HRTX) Upgraded at - MarketBeat

Tue, 15 Nov 2022
7 Penny Stocks to Buy for 10-Bagger Returns - InvestorPlace

Wed, 09 Nov 2022
Can Heron Therapeutics Inc (HRTX) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver

Wed, 09 Nov 2022
Why Heron Therapeutics (HRTX) Stock Is Falling Today - Heron Therapeutics (NASDAQ:HRTX) - Benzinga

Mon, 07 Nov 2022
Notable earnings after Tuesday's close - Seeking Alpha

Fri, 04 Nov 2022
Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends - InvestorPlace

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 119 (M)
Shares Float 95 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 106.1 (%)
Shares Short 28,770 (K)
Shares Short P.Month 33,420 (K)

Stock Financials

EPS -2.3
EPS Est Next Qtl -0.89
EPS Est This Year -3.5
EPS Est Next Year -2.32
Book Value (p.s.) 0.18
Profit Margin (%) -220.6
Operating Margin (%) -211.5
Return on Assets (ttm) -41.7
Return on Equity (ttm) -306.9
Qtrly Rev. Growth 14.3
Gross Profit (p.s.) -0.77
Sales Per Share 0.82
EBITDA (p.s.) -1.73
Qtrly Earnings Growth 0
Operating Cash Flow -155 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -1.21
PEG Ratio -0.1
Price to Book value 14.52
Price to Sales 3.33
Price to Cash Flow -2.13

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.